close
Reading and writing

Nichi GLOW: Japanese beta-glucan, in children with autism spectrum disorders, improves behavior, sleep and gut microbiome in a clinical study | national

TOKYO–(BUSINESS WIRE)–March 14, 2022–

In the first report of its kind, children with autism spectrum disorders (ASD) showed improved behavior, learning abilities and sleep, after oral consumption of AFO-202 strain of black yeast Aureobasidium Pullulans product of beta 1,3 -1,6 glucan (Nichi GLOW), published in BMJ Neurology Open ( http://dx.doi.org/10.1136/bmjno-2021-000203 ). Beneficial replenishment of the gut microbiota has also been reported with Nichi GLOW, which differs from other beta-glucans in its source, method of production and purity.

This press release is multimedia. See the full version here: https://www.businesswire.com/news/home/20220313005031/en/

According to the parents of study participants, improved learning and communication skills, sleep rhythm and quality in addition to interaction with peers were the main changes observed in a clinical study after a 90-day intake of the Nichi GLOW beta-glucan food supplement. One demonstrated his reading, writing and math skills during a follow-up consultation with Dr. Raghavan, a developmental pediatrician and neurologist. ß-glucans considered to remove aggregate alpha-synuclein by enhancing NK cells and as a prebiotic, controls enterobacteriaceae, a cause of disease, therefore may have potential in the fight against neurological diseases involving dysbiosis of the gut microbiome. Nichi GLOW, a safe food supplement, which does not contain any allergens, deserves larger clinical studies with longer follow-up in different populations to be validated as an adjunct to conventional treatment in neurodevelopmental and neurodegenerative diseases, because the intestinal microbiota also varies with dietary habits. , says Dr. Raghavan. (Graphic: Business Wire)

Autism is a neurodevelopmental disorder affecting 1 in 44 children in the developed world, with multiple causes and varying severity of manifestations. These children are more likely to develop neurodegenerative diseases later in life. In the study, Nichi GLOW intake improved CARS score and communication skills ( https://www.youtube.com/watch?v=reJOjBMKSg4 ). Nichi GLOW controlled Enterobacteriaceae, a gut microbiome that produces harmful proteins like curli and amyloid, leading to misfolding and aggregation of alpha-synuclein in neurons, a cause of the disease ( https://doi.org/10.1101/2021.10.26.21265505 ). Synucleinopathy spreading through the gut-brain axis to the brain, could cause Parkinson’s disease or dementia, therefore, it is worth studying the prophylaxis of the Nichi Glucan product line in neurodegenerative conditions, because the activation of microglia is one of the mechanisms of their action in the brain ( https://doi.org/10.1016/j.jns.2021.117554 ), says Dr. Raghavan, the lead researcher.

The results were presented in a webinar commemorating autism sunday ( https://www.ncrmniche.org/autismsunday2022/proceedings/index.html ), organized by the Jesuit Antonyraj Memorial Interdisciplinary Center for Advanced Recovery and Education (JAICARE). Research in Japan has revealed the hidden potentials ( https://doi.org/10.1101/2021.08.05.21261640 ), of this ß-glucan; thanks to a healthy ecosystem in Japan assisting in the development of new solutions, which together with GN Corp’s cross-global interdisciplinary network of healthcare expertise, made this groundbreaking feat possible, the scientists commented. https://sponsored.bloomberg.com/article/jco/japan-where-high-tech-meets-high-value-foreign-direct-investment

The Nichi Glucan product line was approved as a food additive in Japan in 1996 and does not contain any commonly notified allergens. They are unique, being produced as an exo-polysaccharide by new strains of Aureobasidium Pullulans in a GMP certified facility in Japan and exported under various brands: Nichi-GLOW, Neu-REFIX, Nichi Glucan & Nichi Glucan-REFIX; not intended to diagnose, treat, cure or prevent any disease and approval status may vary from country to country. The publications are intended for academic purposes and research initiative; should not be construed as medical advice. A doctor’s advice is recommended for specific health issues.

Show source version on businesswire.com:https://www.businesswire.com/news/home/20220313005031/en/

CONTACT: Samuel JK Abraham

[email protected]

KEYWORD: JAPAN ASIA PACIFIC

INDUSTRY KEYWORD: MENTAL HEALTH RESEARCH SENIORS CHILDREN CLINICAL TRIALS BIOTECHNOLOGY HEALTH CONSUMER SCIENCE

SOURCE: GN Corporation

Copyright BusinessWire 2022.

PUBLISHED: 03/14/2022 02:07 AM/DISC: 03/14/2022 02:07 AM

http://www.businesswire.com/news/home/20220313005031/en

Copyright BusinessWire 2022.

Tags : press releasereading writing
Margarita W. Wilson

The author Margarita W. Wilson